OP0220 Randomized, double-blind, global clinical trial to evaluate equivalence of CHS-1420 to adalimumab in patients with psoriasis and psoriatic arthritis
James R. O’Dell(University of Nebraska Medical Center), Barbara Finck(Coherus BioSciences (United States)), Kristian H. R. Jensen(Coherus BioSciences (United States)), Hong Tang(Coherus BioSciences (United States)), C. Leonardi(Central Dermatology), Alan Kivitz(Altoona Center for Clinical Research), Kim Papp(University of Toronto)
Cited by 3
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis Care & Research|2015|1.1k